<DOC>
	<DOCNO>NCT00690807</DOCNO>
	<brief_summary>PH-10 formulation rise bengal disodium ( RB ) topical administration skin . PH-10 capable undergoing photochemical reaction activate ambient light . This phase 2 study ass whether topical PH-10 apply daily mild , moderate severe area atopic dermatitis ( include atopic eczema ) may ameliorate inflammation skin activate ambient light .</brief_summary>
	<brief_title>A Phase 2 Study PH-10 Treatment Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Men woman , age 18 older . Mild , moderate severe atopic dermatitis . Presence atopic dermatitis area outside head face baseline Investigator Global Assessment ( IGA ) 2 ( mild disease ) , 3 ( moderate ) 4 ( severe disease ) screening . Written inform consent subject legal guardian . Women pregnant , attempt conceive , nursing infant . Subjects receive phototherapy ( UVB , PUVA ) systemic therapy ( immunosuppressant , cytostatics , corticosteroid ) within 4 week . Subjects receive systemic antibiotic within 2 week . Subjects receive topical therapy ( tar , corticosteroid ) within 7 day . Subjects receive investigational drug clinical research study within 4 week . Subjects receive agent pose clinically significant risk photosensitivity reaction within 5 halflives initiation study treatment . Subjects history porphyria , systemic lupus erythematosus xeroderma pigmentosum . Subjects clinical condition may pose health risk subject involve study detrimentally affect regular followup subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>eczema</keyword>
</DOC>